Investigating aggressive breast cancer in women of African descent
Full Project 1
This study is looking at how certain aggressive breast cancers, especially in women of African descent, behave and resist treatment, with the goal of finding new ways to improve therapies by focusing on specific parts of a protein called MYC.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project ID | NIH-10933470 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms behind aggressive luminal B breast cancers, particularly in women of African descent. It aims to identify specific acetylation sites on the MYC protein that contribute to cancer progression and resistance to therapies. By studying these molecular pathways, the research seeks to uncover new targets for drug development that could improve treatment outcomes for affected patients. The approach includes analyzing cancer cells and their signaling processes to better understand how they grow and resist current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are women of African descent diagnosed with luminal B breast cancer, particularly those with aggressive forms of the disease.
Not a fit: Patients with other types of breast cancer or those not of African descent may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates for women suffering from aggressive breast cancer.
How similar studies have performed: While there have been challenges in targeting MYC in cancer treatment, this research aims to explore novel mechanisms that have not been extensively tested, making it a potentially groundbreaking approach.
Where this research is happening
Riverside, United States
- University of California Riverside — Riverside, United States (Active)
Researchers
- Principal investigator: Martinez, Ernest — University of California Riverside
- Study coordinator: Martinez, Ernest
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.